Table 1.
Studies summarizing outcomes with SABR for primary localized or locally advanced RCCs.
| Author (Year) | Study Type | No. of Patients (N) | Follow-Up Duration (Months) |
Dose (Gy)/No. of Fractions | Grade 3+ Toxicity (%) | Local Control (%) | Comments, Study Population |
|---|---|---|---|---|---|---|---|
| Grelier et al. (2021) [44] | Retrospective | 23 | 22 | 35/5–7 | 0 | 96 | Frail patients unfit for surgery or other ablative therapies |
| Grubb et al. (2021) [49] | Prospective | 11 | 34.3 | 48/3 54/3 60/3 |
9.1 | 90 | Poor surgical candidates |
| Swaminath et al. (2021) [45] | Prospective | 28 | NA | 30–42/ 3–5 |
NA | NA | 13 patients ≤ 4 cm, 19 with >4 cm tumors |
| Margulis et al. (2021) [50] | Prospective | 6 | 24 | 40/5 | 0 | NA | Neoadjuvant SABR for patients with IVC_TT |
| Tetar et al. (2020) [48] | Retrospective | 36 | 16.4 | 40/5 | 0 | 95.2 | MRI-guided SABR, 31 patients had ≥T1b disease |
| Siva et al. (2020) [47] | Retrospective | 95 | 32.4 | ____ | 0 | 97.1 | Large (>4 cm), T1b or higher tumors |
| Senger et al. (2019) [43] | Retrospective | 10 | 27 | 24–25/1 36/3 |
0 | 92.3 | 7 with T1a and 3 with T3a disease |
| Hannan et al. (2023) [51] | Prospective | 16 | 36 | 36/3 or 40/5 | 0 | 94 (1-year) | ≤5 cm enlarging primary RCC |
| Siva et al. (2023) (FASTRACK II; Abstract only) [52] | Prospective | 70 | 42 | 26/1 (≤4 cm) 42/3 (>4 cm) |
10 | 100 | Non-surgical, T1b+ patients mostly |